To investigate the population pharmacokinetics of the antimalarial halofantrine (HF) in healthy volunteers and patients with symptomatic falciparum malaria.
This apparent contradiction led us to examine key elements of the trial methodology in the context of established guidelines on the conduct and reporting of randomized controlled trials.
The overall pharmacokinetic properties of piperaquine in this study were consistent with previously published reports in non-pregnant patients.
Of 630 patients with P. falciparum enrolled in the trial of thiamin treatment, 549 (87%, 357 children [less than or equal to]15 years and 192 adults) were included in this study.
The study showed a significant decreased parasitaemia in patients treated with PR 29 CT1 and artesunate-amodiaquine with adequate clinical parasitological responses (APCR) at day 14 of 87.9 and 96.9 %, respectively.
This paper describes the case of an HIV-infected patient with severe falciparum malaria who was diagnosed with haemolytic anaemia after treatment with oral artemether-lumefantrine.
We report a case of falciparum malaria in a traveler 9 days after successful treatment of ovale malaria.
We report a successful treatment of severe falciparum malaria in a non-immune adult patient with 30% parasitemia treated with the 6-dose oral regimen of artemether plus lumefantrine combination therapy alone.
Dihydroartemisinin-piperaquine is being increasingly used as a first-line artemisinin combination treatment for malaria.
The aim of this study was to describe the pharmacokinetic and pharmacodynamic properties of piperaquine in 236 children with uncomplicated falciparum malaria in Burkina Faso.
